|
Jul 28
|
This is the Most Dangerous Week for Investors in 20 Years
|
|
Jul 25
|
S&P 500 Gains and Losses Today: Deckers Stock Jumps as Global Footprint Grows; Intel Shares Sink
|
|
Jul 24
|
Deckers Brands Reports First Quarter Fiscal Year 2026 Financial Results
|
|
Jul 21
|
EdgeOne Medical Announces Appointment of Michael Denzer as VP, Client Relations to Further Elevate Product Innovation and Client Partnerships
|
|
Jul 21
|
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
|
|
Jul 18
|
Trump Aims Tariff Double Whammy at Industries, Nations by Aug. 1
|
|
Jul 16
|
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
|
|
Jul 14
|
Deckers Brands Announces Conference Call to Review First Quarter Fiscal 2026 Earnings Results
|
|
Jul 11
|
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
|
|
Jun 17
|
Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy
|
|
Jun 17
|
Generic Drugmakers Resist Trump’s Calls for More U.S. Manufacturing
|
|
Jun 17
|
Teva, Fosun Pharma partner to develop TEV-56278
|
|
Jun 17
|
Teva to collaborate with Fosun Pharma for TEV-56278
|
|
Jun 16
|
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
|
|
Jun 16
|
Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters
|
|
May 29
|
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
|
|
May 28
|
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate
|
|
May 28
|
Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead
|
|
May 28
|
Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408
|
|
May 27
|
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
|